The GLP-1 era has been genuinely transformative for weight loss medicine. The clinical outcomes data on semaglutide and tirzepatide is compelling, the patient demand is real, and practices that built GLP-1 programs early have seen significant revenue growth. But as the GLP-1 market matures — as supply stabilizes, competition increases, and more clients complete initial treatment cycles — the practices that differentiated themselves in the next phase of the conversation will be the ones that understood GLP-1 was the beginning of the body composition story, not the end of it.
The peptide research landscape offers a coherent set of tools for extending that conversation. Not as GLP-1 replacements, but as research protocols addressing the body composition questions that appetite suppression alone doesn’t answer.
Free Peptide Research Guide 2026/2027
Download our comprehensive research guide — evidence-based peptide science insights for healthcare practitioners and researchers.
What GLP-1 Protocols Don’t Address
GLP-1 agonists produce weight loss primarily through appetite suppression and delayed gastric emptying. The caloric deficit that results drives fat reduction. But several body composition variables remain unaddressed by this mechanism alone:
Lean mass preservation. Significant caloric restriction — even with protein-forward dietary guidance — is associated with lean mass loss. Studies on GLP-1 protocols have documented meaningful muscle mass reduction alongside fat reduction in many subjects. For clients focused on body composition rather than just body weight, this is a significant variable that appetite suppression doesn’t solve.
Post-treatment weight maintenance. GLP-1 agonists require ongoing use to maintain their effects. Clients who discontinue — whether due to cost, side effects, or reaching a goal weight — face a well-documented rebound risk. The research question of how to support metabolic function and body composition during and after GLP-1 discontinuation is one the field hasn’t fully answered.
Skin integrity during rapid loss. As discussed extensively in post-GLP-1 skin research, clients losing 15-25% of body weight rapidly frequently experience skin laxity, thinning, and textural changes that don’t resolve without specific intervention. This is a collagen biology problem that falls outside GLP-1’s mechanism entirely.
Fat-distribution specificity. GLP-1 protocols produce overall fat reduction but don’t specifically target resistant fat deposits or address the body composition picture clients are ultimately trying to achieve. The body recomposition question — preserving or building lean mass while reducing remaining fat after initial weight loss — is a research area with active investigation and no simple answer.
The Peptide Research Protocols Worth Understanding
CJC-1295 + Ipamorelin: Growth Hormone Secretagogue Research
CJC-1295 is a GHRH (growth hormone releasing hormone) analog that stimulates the pituitary to produce and release growth hormone. Ipamorelin is a GHRP (growth hormone releasing peptide) that acts through a different receptor — the ghrelin receptor — to amplify GH pulsatility. The combination is studied for its synergistic effect on GH secretion: CJC-1295 extends the duration of GH release while Ipamorelin increases the amplitude of GH pulses.
The body composition research rationale for GH secretagogues centers on GH’s established role in lean body mass maintenance and fat metabolism. Preclinical and early human research on CJC-1295 + Ipamorelin has investigated effects on lean body mass, fat reduction, sleep quality (GH is primarily released during deep sleep), and recovery. For post-GLP-1 clients focused on maintaining lean mass and continuing fat metabolism progress, this combination represents the most mechanistically grounded research protocol in the weight management space.
Available through Hello Stacks for research use only.
AOD-9604 / Fragment 176-191: Fat Metabolism Research
As covered in our deeper research piece on these compounds, AOD-9604 and Fragment 176-191 are C-terminal fragments of human growth hormone that appear to retain the lipolytic (fat breakdown) signaling of the parent hormone while being substantially inert to GH’s glucose-regulatory effects. Preclinical research has investigated their effects through beta-3 adrenergic receptor pathways in adipose tissue.
For weight loss clinics, these compounds represent the “fat-mechanism-specific” research conversation — tools that may address fat metabolism directly rather than through the caloric deficit pathway that GLP-1 creates. For clients in the post-GLP-1 body recomposition phase, the research question of whether fat-metabolism-specific compounds produce different outcomes than continued caloric restriction is a substantive one.
BPC-157: Tissue Repair for the Post-Loss Client
BPC-157’s relevance to the weight loss clinic context isn’t primarily about body composition — it’s about the tissue repair consequences of significant weight loss. Preclinical research has investigated BPC-157’s effects on tendon and ligament repair, wound healing, vascular integrity, and gut health. For clients who’ve been on extended caloric restriction and who present with GI complaints (common on GLP-1 protocols), musculoskeletal deconditioning, or the skin laxity and tissue changes that accompany rapid weight loss, BPC-157 represents a research compound with a broad tissue-repair mechanism that’s relevant to the whole-body consequences of their weight loss journey.
Building the Research Protocol Tier
The service architecture that works for weight loss clinics adding peptide research protocols is straightforward: position them as the “what comes after” conversation — the research protocols that address the body composition and tissue integrity questions that GLP-1 treatment raises but doesn’t resolve.
This framing works for three client segments that every weight loss clinic is already managing:
Active GLP-1 clients focused on lean mass preservation alongside fat reduction. The CJC-1295 + Ipamorelin research conversation is most relevant here — supporting the anabolic side of the equation while GLP-1 handles the caloric deficit.
Post-GLP-1 clients who’ve reached their weight goal and are now focused on body recomposition and maintenance. AOD-9604, CJC-1295 + Ipamorelin, and BPC-157 all have relevant research profiles for this phase.
GLP-1-adjacent clients who are interested in weight management but not pursuing GLP-1 protocols — whether due to cost, side effects concerns, or personal preference. For this segment, the body composition research conversation offers an evidence-grounded alternative that extends your practice’s relevance.
Want to talk through building a peptide research protocol tier for your weight loss practice? Reach out to Ted at 725.275.7267 | hellostacks.com | stackone.com
All compounds referenced are for research use only. Not FDA-approved for any clinical application. Nothing here constitutes medical or clinical advice. Consult qualified professionals before implementing any protocol in a clinical setting.